PF-Atlas › Clinical Trials › NCT01265888

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.

Inhaled Nitric Oxide · Phase 2

Registry ID
NCT01265888
Phase
Phase 2
Status
Completed
Drug / intervention
Inhaled Nitric Oxide
Sponsor
Geno LLC
Start
2011-03
Enrollment
31
Locations
10

About this trial

A Phase 2 open label, dose escalation study to find the minimally and maximum effective dose (dose beyond which no further effect on PVR is seen) of inhaled nitric oxide generated by the GeNOsyl® System compared to placebo.

View NCT01265888 on ClinicalTrials.gov →

Explore related

All Inhaled Nitric Oxide trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT01265888 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.